Working on a stack? Use the free Compound reconstitution calculator — half-life graph, cost-per-mcg comparator, syringe visualization. RUO context only. No dosing on the public side.
The Quote
"I'm a big fan of peptides. I think there are 14 banned peptides that are coming back."
That is Robert F. Kennedy Jr. on Joe Rogan, episode 2461, recorded 2026-02-27.
The mainstream press wave hit six weeks later. WaPo, CBS, NPR, NBC, PBS, BioPharma Dive, CNN, STAT — all on or around 2026-04-15, all running variants of the same headline. The next regulatory beat is 2026-07-23 and 24, when the FDA Pharmacy Compounding Advisory Committee meets and the reclassification conversation moves from talk-show clip to docket.
Why this matters in two paragraphs
The story has been covered as a headline. It has not been covered as a list. Search any of those eight outlets for the actual fourteen compounds and you find the same sentence reprinted across the wire. None of them publish the per-compound profile a serious operator needs to read this story.
That is the gap. The mainstream press has the news beat. Reddit has the panic beat — r/Peptides, r/Retatrutide, r/tirzepatidecompound have been arguing about this for a month with no structured anchor to argue against. The Brief plants its flag here. Issue 1 is the list, decoded — name, mechanism class, half-life, primary literature anchor, status as of today, why it matters. Fourteen rows. No dosing. Public issue.
Topol's objection, conceded
Eric Topol published the loudest skeptic essay against this whole class of writing. The line readers will quote at me: "There is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated."
He is right about the RCT gap. He is right that most of what gets written about peptides treats animal data, open-label case series, and Reddit field reports as if they sit at the same level as a phase 3 trial. They do not.
The Brief works on a tiered-evidence framework, named once, applied every issue. Tier 1 is randomized controlled trials in humans. Tier 2 is open-label studies and case series. Tier 3 is animal models and mechanistic work. Tier 4 is operator n=1 and aggregated practitioner reports. Each tier earns a different weight in a stack decision. Most of the fourteen compounds below are Tier 3 with a thin Tier 2 layer; a few have Tier 1 on a narrow indication and Tier 3 on the wider claims. None of that is hidden. None of that is fixed by reclassifying them. It is the math operators are choosing to do under their own labs, with their own physician relationships, eyes open.
The list of fourteen
A standing note before the table. RFK's "fourteen banned peptides" line has not been published as an official FDA list. The agency has not released a roster under that label as of this issue's send date. The names below are this Brief's best reconstruction from the press wave, the public Compounding Advisory Committee record, the Reddit and Instagram corpus, and the Hill / BioPharma Dive coverage. Where the public signal is thin, I flag the uncertainty in the row. Authority on this beat comes from honest sourcing, not from inventing a roster.
Dosing lives behind the email gate. Public mechanisms only here.
# | Name (alias) | Mechanism class | Half-life | Primary literature anchor | Status (2026-05-03) | Why this matters |
|---|---|---|---|---|---|---|
1 | BPC-157 | Pentadecapeptide; modulates VEGF, NO, growth factor pathways tied to GI and connective-tissue repair | ~4 hours (oral/parenteral, short) | Sikiric BPC-157 GI and tendon work, 2010s | RUO-only; 503A excluded under FDA bulks rejection | The flagship "the case to bring back" compound; the Tier 3 evidence is real, the Tier 1 evidence is not. |
2 | TB-500 / Thymosin Beta-4 | Actin-sequestering peptide; tissue repair, angiogenesis | ~2 hours plasma; downstream effects longer | Goldstein thymosin work, 1980s–2010s | RUO-only; 503A excluded | Paired with BPC-157 in the so-called Wolverine stack; receptor pharmacology is messier than the marketing. |
3 | CJC-1295 (with or without DAC) | GHRH analog | Without DAC: ~30 min. With DAC: measured in days. | Teichman / Sackmann-Sala GHRH analog work, 2000s–2010s | RUO-only | Long-acting GHRH was the textbook tonic-vs-pulsatile receptor mismatch I covered in welcome email three. |
4 | Ipamorelin | Selective GHRP / ghrelin receptor agonist | ~2 hours | Raun / Hansen ghrelin-receptor work, 1990s–2000s | RUO-only; 503A excluded | Cleanest GH-axis tool in the category; the receptor wants pulses, the calendar wants daily, and the calendar usually wins. |
5 | Sermorelin | GHRH(1–29) analog | ~10–20 min | Frohman / Thorner GHRH work, 1980s–2000s | Was 503A available; status under active review | One of the few peptides on this list with a real Tier 1 indication (pediatric GHD). The over-50 longevity-clinic use case is a different question. |
6 | Tesamorelin | Stabilized GHRH analog | ~30 min plasma; downstream effects longer | Falutz HIV lipodystrophy trials, 2000s–2010s | FDA-approved (Egrifta) for HIV lipodystrophy | The one with a real RCT base on its labeled indication; off-label longevity use is the contested layer. |
7 | GHK-Cu | Copper tripeptide; modulates skin remodeling, fibroblast and stem-cell behavior | Topical: minutes to hours | Pickart copper tripeptide work, 1970s–2010s | RUO-only for injectable; topical cosmetic use widespread | The skin-and-hair flagship; r/Peptides 567 upvote thread on five-week seb derm clearance is the kind of Tier 4 signal that drives the buy. |
8 | Selank | Synthetic analog of tuftsin; modulates GABAergic and serotonergic tone | Plasma: under 1 hour. Downstream effects longer; intranasal route changes the input function. | Russian Academy of Sciences tuftsin and Selank work, 1980s–2010s | RUO-only; not US-approved | Cognition / anxiolysis lane; literature is heavily Russian, which Topol is right to flag and operators still buy on anyway. |
9 | Semax | ACTH(4–10) analog; modulates BDNF and dopaminergic tone | Plasma: minutes (intranasal) | Russian Academy of Sciences Semax work, 1980s–2010s | RUO-only; not US-approved | Same lane as Selank with a different receptor profile. Same literature caveat. |
10 | Epitalon | Synthetic tetrapeptide; modulates telomerase and pineal-axis signaling | Short plasma half-life | Khavinson bioregulator work, 1990s–2010s | RUO-only | The longevity flagship of the Khavinson bioregulator program; Niddam owns this lane on Instagram nearly alone. |
11 | Thymosin Alpha-1 | Immunomodulator; T-cell maturation pathways | ~2 hours | Goldstein / Garaci thymalfasin work, 1970s–2010s | FDA orphan designations; approved in many countries (Zadaxin); 503A excluded in US | One of the few that crosses Tier 1 in non-US jurisdictions; US status is the contested piece. |
12 | MOTS-c | Mitochondrial-derived peptide; modulates AMPK and metabolic homeostasis | Short plasma; tissue distribution longer | Lee / Cohen MOTS-c work, 2010s | RUO-only | Mitochondrial-medicine flagship; r/Peptides anaphylaxis reports are the operator-level safety signal nobody is aggregating. |
13 | Kisspeptin-10 | KISS1R agonist; upstream of GnRH and the HPG axis | Plasma: minutes | Dhillo / Seminara kisspeptin reproductive-axis work, 2000s–2010s | Investigational in active trials; RUO-only outside trials | The compound mainstream coverage is missing entirely; Phase 2 reproductive-axis data is real, the longevity adjacency is the speculative layer. |
14 | Follistatin (or DSIP — flag the uncertainty) | Follistatin: myostatin-pathway antagonist. DSIP: delta sleep-inducing peptide. | Follistatin: variable by construct. DSIP: ~7 min. | Lee myostatin-pathway work, 2000s–2010s. Schoenenberger DSIP work, 1970s. | RUO-only; gene-therapy follistatin programs in trial separately | This is the row I'm least certain about. The press coverage waves at "follistatin-class" without naming a construct; some lists swap in DSIP for the sleep lane. Flagging openly. |
A reader who cares about the "is this really the list" question should read the row above as it is written: this is the Brief's reconstruction. When the FDA publishes the actual roster — at the 2026-07-23/24 advisory meeting or in the docket leading up to it — I will publish a corrections issue with the deltas line by line. That is the beat.
The BTLabs flag (and where Issue 2 picks up)
BTLabs ran independent identity testing on a basket of unapproved peptide vials in the public RUO market. Their headline number, as covered in The Hill: at least one in five vials tested were mislabeled. Vials labeled retatrutide that contained semaglutide. Vials labeled one peptide that contained a different one entirely. Twenty percent.
That is the number that matters before any reclassification matters. If RFK and the FDA reinstate kisspeptin-10 to a compounding category in August, and the COA on the vial is a sticker, the reclassification is a press release and the operator is still pinning whatever the vendor put in the box.
Issue 2 is the COA-read. The five things I check on any certificate before I pin anything, in ninety seconds. The vendor audit holds regardless of which of the fourteen above gets reclassified first.
The CTA
Reply to this email with the number — one through fourteen — of the compound you most want decoded next. Not a vote in the abstract. The replies steer the calendar; the most-requested compound becomes the deep-dive issue inside the next four weeks. Highest-value reply this week sets next month's beat.
Colby
—
For research use only. Not medical advice. Compounds discussed are sold for research purposes; nothing here is a recommendation to use them on humans or animals. The team behind The Compound also operates an RUO peptide vendor; that relationship is disclosed on the about page and applied to every issue under the Conflict Test.